▴ Insulin aspart is a recombinant analogue of human insulin. Following subcutaneous insulin injection (0.15 to 0.2 U/kg), significantly higher serum insulin concentrations are achieved in a shorter time with insulin aspart than with human insulin. The subsequent decline in serum insulin concentrations is also more rapid with insulin aspart.
▴ In healthy individuals undergoing euglycaemic glucose clamp testing, glucose infusion rates were higher and reached maximum concentrations significantly earlier after insulin aspart than after human insulin.
▴ Interindividual variability in pharmacodynamic and pharmacokinetic parameters with insulin aspart was generally less than that with human insulin, whereas the intraindividual variability in these parameters was similar after each insulin.
▴ In patients with type 1 diabetes postprandial glucose excursions were less pronounced with insulin aspart than human insulin. Daytime glucose control was better and minimum glucose levels during the night were not as low with insulin aspart as with human insulin.
▴ In diabetic patients treated with insulin aspart there was generally a lower frequency of hypoglycaemic events than in patients treated with human insulin.
KeywordsAdis International Limited Human Insulin Insulin Analogue Insulin Aspart Hypoglycaemic Event
Unable to display preview. Download preview PDF.
- 4.Drejer K. Bioactivity of insulin analogues. In: Berger M, Gries FA, editors. Frontiers in insulin pharmacology: international symposium, Hamburg. Stuttgart: Georg Thieme Verlag, 1993: 17–27Google Scholar
- 9.Home P, Barriocanal L, Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Eur J Clin Pharmacol (In press)Google Scholar
- 11.Lindholm A, McEwen J, Riis A. Significantly improved postprandial glycaemic control with the novel rapid-acting insulin aspart [abstract]. Diabetologia 1998 Aug; 41 Suppl. 1: A49Google Scholar
- 14.Rosenfalck AM, Thorsby P, Kjems L, et al. Effects of the rapid-acting insulin analogue insulin aspart on postprandial glycaemic excursions compared to human soluble insulin actrapid given immediately or 30 minutes before a meal in insulin treated type 2 diabetes patients. Acta Diabetologica [abstract]. 1998; 35(4): 246Google Scholar
- 15.Lutterman J, Pijpers E, Netten P, et al. Glycaemic control in IDDM patients during one day with injection of human insulin or the insulin analogues insulin X14 and insulin X14(+Zn). In: Berger M, Gries F, editors. Frontiers in insulin pharmacology: international symposium, Hamburg. Stuttgart: Thieme Medical Publishers, 1993: 102–9Google Scholar
- 18.Ewing FME, Frier BM. Comparison of the physiological and symptomatic responses to hypoglycaemia induced by human soluble insulin and the insulin analogue aspart in patients with type 1 diabetes [abstract]. Diabetic Med 1998; 15 Suppl. 2: S34Google Scholar